Searchable abstracts of presentations at key conferences in endocrinology

ea0005p186 | Neuroendocrinology and Behaviour | BES2003

Effect of the novel somatostatin ligand, SOM230, on rat & human anterior pituitary hormone secretion

Murray R , Kim K , Ren S , Weckbecker G , Bruns C , Melmed S

The clinically available somatostatin (SRIF) analogues, octreotide and lanreotide, are the mainstay of treatment for patients with acromegaly in whom surgery has failed to adequately control GH and IGF-I levels or where surgery is contra-indicated. Both analogues exhibit selective high affinity for SRIF receptor subtype 2 (SSTR2). GH and TSH secretion are regulated by SSTR subtypes 2 & 5, with an additional effect on GH secretion via SSTR1. Prolactin is regulated by SSTR5 ...